PAPER Burke D

ACP Journal Club. Review: Several brief screening tests detect dementia in older adults; no trials assess effects on patient outcomes.

Ann Intern Med. 2014 Feb 18;160(4):JC12. PubMed: 24534934

PAPER Yamashita C, Tomiyama H, Funayama M, Inamizu S, Ando M, Li Y, Yoshino H, Araki T, Ichikawa T, Ehara Y, Ishikawa K, Mizusawa H, Hattori N

The evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease.

Neurobiol Aging. 2014 Jul;35(7):1779.e17-21. Epub 2014 Jan 25 PubMed: 24534762

PAPER Takeuchi T, Popiel HA, Futaki S, Wada K, Nagai Y

Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.

Curr Med Chem. 2014;21(23):2575-82. PubMed: 24533807

PAPER Jörg M, Scammells PJ, Capuano B

The Dopamine D2 and Adenosine A2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease.

Curr Med Chem. 2014 Feb 16; PubMed: 24533801

Yolande Haydon

GliaCure, Inc
BOSTON, United States

Drug Appears Safe in Huntington’s; Experts Split on Functional Benefit

RESEARCH NEWS 2014-02-19 Research News On February 18, Prana Biotechnology reported top line  results of its Reach2HD  Phase 2 clinical trial. This trial investigated the safety and tolerability of PBT2  in patients with Huntington’s disease (HD), a progressive form of neurodegen

PAPER Mosser DM, Edwards JP

Exploring the full spectrum of macrophage activation.

Nat Rev Immunol. 2008 Dec;8(12):958-69. PubMed: 19029990

PAPER Gordon S

Alternative activation of macrophages.

Nat Rev Immunol. 2003 Jan;3(1):23-35. PubMed: 12511873

PAPER Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL

Identification of a unique TGF-β-dependent molecular and functional signature in microglia.

Nat Neurosci. 2014 Jan;17(1):131-43. Epub 2013 Dec 8 PubMed: 24316888

Gary Landreth on Transcriptome-based network analysis reveals a spectrum model of human macrophage activation.

COMMENT In the last decade, there has been a fundamental reevaluation of the origins and biology of microglia. Recent work has provided substantial new understanding about the critical roles these cells play in central nervous system disease and injury. In the pa

Annamaria Costa

United Kingdom

TREM2 Variant Doubles the Risk of ALS

RESEARCH NEWS 2014-02-19 Research News Researchers have added amyotrophic lateral sclerosis (ALS) to the list of neurodegenerative diseases for which the immunomodulatory gene TREM2 is a risk factor. Writing in the February 17 JAMA Neurology, researchers led by Matthew Harms at W

PAPER Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB

TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis.

JAMA Neurol. 2014 Apr;71(4):449-53. PubMed: 24535663

PAPER Rossner S, Hartlage-Ruebsamen M, Schilling S, Demuth HU

Glutaminyl Cyclase as novel pharmacological target for AD therapy.

P13 Clinical Trials on Alzheimer’s Disease, Toulouse, 4th Nov. 2010.

Denise Fleig

Pharmacovigilance
United Kingdom